Andreas G. Bader

12.0k citations

58 papers · 8.9k indexed · 9 hit papers · h-index 30

Impact in

Cancer Research top 0.1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Molecular Biology top 0.5%
- Circular RNAs in diseases
- RNA Interference and Gene Delivery
- RNA modifications and cancer
- PI3K/AKT/mTOR signaling in cancer
- Advanced biosensing and bioanalysis techniques
- RNA Research and Splicing

Papers in

Cancer Research 31
- MicroRNA in disease regulation 30
- Cancer-related molecular mechanisms research 6
Molecular Biology 45
- RNA Interference and Gene Delivery 14
- RNA modifications and cancer 13
- Circular RNAs in diseases 10
- RNA Research and Splicing 9
- PI3K/AKT/mTOR signaling in cancer 7

Co-authors: Peter K. Vogt Sohye Kang David Brown Kevin Kelnar Jason F. Wiggins Lubna Patrawala Li Zhao David T. Brown
Journals: Cancer Research (6 papers)Oncogene (5 papers)Proceedings of the National Academy of Sciences (4 papers)Molecular Therapy (4 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States Canada Austria

In The Last Decade

Andreas G. Bader

57 papers receiving 8.7k citations

Hit Papers

9 papers align trajectories log scale

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors 2016 · 682 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Investigational New Drugs
2015 JNCI Journal of the National Cancer Institute
2012 Frontiers in Genetics
2011 Molecular Therapy
2011 Nature Medicine
2010 Cancer Research
2010 Cancer Research
2005 Proceedings of the National Academy of Sciences
2005 Nature reviews. Cancer

Peers

Countries citing papers authored by Andreas G. Bader

Since Specialization

Citations

This map shows the geographic impact of Andreas G. Bader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas G. Bader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas G. Bader more than expected).

Fields of papers citing papers by Andreas G. Bader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas G. Bader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas G. Bader. The network helps show where Andreas G. Bader may publish in the future.

Co-authors

The 25 scholars most cited alongside Andreas G. Bader, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andreas G. Bader Line = papers co-authored together Andreas G. Bader links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function Scientific Reports ·Trevor M. Morey, Tania Benatar, Stacey X. Xu, Ling Wang, Philbert Ip, Thanyashanthi Nitya-Nootan, Gargi Thakor, Andreas G. Bader, Christopher W. Helsen, Walid A. Houry	2025	1
2	Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors Cancer Immunology Research ·Stacey X. Xu, Ling Wang, Philbert Ip, Ritu R. Randhawa, Tania Benatar, Suzanna L. Prosser, Prabha Lal, Alima Naim Khan, Thanyashanthi Nitya-Nootan, Gargi Thakor, Heather MacGregor, Danielle L Hayes, Andrea Vucicevic, Princy Mathew, Sadhak Sengupta, Christopher W. Helsen, Andreas G. Bader	2024	2
3	Abstract 3188: Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors Cancer Research ·Ling Wang, Stacey X. Xu, Tania Benatar, Ritu R. Randhawa, Philbert Ip, Prabha Lal, Thanyashanthi Nitya-Nootan, Laura Ravensbergen, Heather MacGregor, Suzy Prosser, Sadhak Sengupta, Christopher W. Helsen, Andreas G. Bader	2023	1
4	Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer Lung Cancer ·Jane Zhao, Adriana Guerrero, Kevin Kelnar, Heidi J. Peltier, Andreas G. Bader	2017	35
5	Down-regulation of target gene expression in human white blood cells (hWBCs) by MRX34, a liposomal miR-34 mimic: Next generation sequencing (NGS) results from a first-in-human trial of microRNA cancer therapy Annals of Oncology ·Kevin Kelnar, Heidi J. Peltier, Andreas G. Bader	2016	2
6	Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Cultured Non-Small Cell Lung Cancer Cells Methods in molecular biology ·Jane Zhao, Andreas G. Bader	2016	5
7	PDL1 Regulation by p53 via miR-34 JNCI Journal of the National Cancer Institute ·María Angélica Cortez, Cristina Ivan, David R. Valdecanas, Xiaohong Wang, Heidi J. Peltier, Yuping Ye, Luiz H. Araujo, David P. Carbone, Konstantin Shilo, Dipak Kumar Giri, Kevin Kelnar, Desiree Martin, Ritsuko Komaki, Daniel R. Gomez, Sunil Krishnan, George A. Călin, Andreas G. Bader, James W. Welsh Hit paper breakdown →	2015	535
8	Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer Molecular Therapy ·María Angélica Cortez, David R. Valdecanas, Xiaochun Zhang, Yanai Zhan, Vikas Bhardwaj, George A. Călin, Ritsuko Komaki, Dipak Kumar Giri, Caio C. Quini, Tatiana Wolfe, Heidi J. Peltier, Andreas G. Bader, John V. Heymach, Raymond E. Meyn, James W. Welsh	2014	162
9	In-Depth Analysis Shows Synergy between Erlotinib and miR-34a PLoS ONE ·Jane Zhao, Kevin Kelnar, Andreas G. Bader	2014	60
10	A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer Oncogene ·Andrea L. Kasinski, Kevin Kelnar, Carlos Stahlhut, Esteban A. Orellana, J Zhao, E Shimer, Sarah Dysart, X Chen, Andreas G. Bader, Frank J. Slack	2014	173
11	TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1 Molecular Therapy ·Jane Zhao, Paul Lammers, Chris Torrance, Andreas G. Bader	2013	46
12	miR-34 – a microRNA replacement therapy is headed to the clinic Frontiers in Genetics ·Andreas G. Bader Hit paper breakdown →	2012	562
13	Developing therapeutic microRNAs for cancer Gene Therapy ·Andreas G. Bader, David T. Brown, Jay Stoudemire, Paul Lammers	2011	257
14	Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34 Cancer Research ·Jason F. Wiggins, Lynnsie Ruffino, Kevin Kelnar, Michael Omotola, Lubna Patrawala, David Brown, Andreas G. Bader Hit paper breakdown →	2010	532
15	Phosphatidylinositol 3-Kinase: The Oncoprotein Current topics in microbiology and immunology ·Peter K. Vogt, Jonathan R. Hart, Marco Gymnopoulos, Hao Jiang, Sohye Kang, Andreas G. Bader, Li Zhao, Adam Denley	2010	90
16	Regression of murine lung tumors by the let-7 microRNA Oncogene ·Phong Trang, Pedro P. Medina, Jane F. Wiggins, Lynnsie Ruffino, Kevin Kelnar, Michael Omotola, Robert Homer, David Brown, Andreas G. Bader, Joanne B. Weidhaas, Frank J. Slack	2009	398
17	Applying small RNA molecules to the directed treatment of human diseases: realizing the potential Expert Opinion on Therapeutic Targets ·Todd C. Pappas, Andreas G. Bader, Bernard F. Andruss, David Brown, Lance P. Ford	2007	24
18	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proceedings of the National Academy of Sciences ·Sohye Kang, Andreas G. Bader, Peter K. Vogt Hit paper breakdown →	2005	642
19	Phosphoinositide 3-kinase: From viral oncoprotein to drug target Virology ·Peter K. Vogt, Andreas G. Bader, Sohye Kang	2005	32
20	Conditional Cell Transformation by Doxycycline-Controlled Expression of the ASV17 v-jun Allele Virology ·Andreas G. Bader, Markus Hartl, Klaus Bister	2000	7

About Andreas G. Bader

Andreas G. Bader is a scholar working on Cancer Research, Molecular Biology, Oncology, Genetics and Immunology, having authored 58 papers that have together received 8.9k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (30 papers), RNA Interference and Gene Delivery (14 papers), RNA modifications and cancer (13 papers), Circular RNAs in diseases (10 papers), RNA Research and Splicing (9 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), CAR-T cell therapy research (6 papers) and Cancer-related molecular mechanisms research (6 papers). The work is most often cited by research in Cancer Research (5.3k citations), Molecular Biology (7.2k citations), Oncology (1.6k citations), Genetics (448 citations) and Immunology (616 citations). Andreas G. Bader has collaborated with scholars based in United States, Canada and Austria. Frequent co-authors include Peter K. Vogt, Sohye Kang, David Brown, Kevin Kelnar, Jason F. Wiggins, Lubna Patrawala, Li Zhao, David T. Brown, Michael Omotola and Matthew Winkler. Their work appears in journals such as Cancer Research, Oncogene, Proceedings of the National Academy of Sciences, Molecular Therapy and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact